Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived XenograftsShunqiang Li, Ana M. González-Angulo, Jingqin Luo et al.|Cell Reports|2013Cited by 630
Supplementary Table S3 from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast CancerX. Cynthia, Matthew J. Ellis, Feng Gao et al.|Unknown|2023Cited by 0
Supplementary Table S3-4 caption from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast CancerX. Cynthia, Matthew J. Ellis, Feng Gao et al.|Unknown|2023Cited by 0
Supplementary Table S4 from NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast CancerX. Cynthia, Matthew J. Ellis, Feng Gao et al.|Unknown|2023Cited by 0
Supplementary Figure S1 from A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast CancerX. Cynthia, Matthew J. Ellis, Jingqin Luo et al.|Unknown|2023Cited by 0